Optimization of carboxylate-terminated poly(amidoamine) dendrimer-mediated cisplatin formulation

References

• Reedijk J. New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc Natl Acad Sci USA 2003;100:3611–16
   PubMed Web of Science ®Google Scholar
• Gordon M, Hollander S. Review of platinum anticancer compounds. J Med 1993;24:209–65
   PubMedGoogle Scholar
• Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000;59:9–17
   PubMed Web of Science ®Google Scholar
• Gianasi E, Wasil M, Evagorou EG, et al. HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer 1999;35:994–1002
   PubMed Web of Science ®Google Scholar
• Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev 1999;99:2451–66
   PubMed Web of Science ®Google Scholar
• Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467–98
   PubMed Web of Science ®Google Scholar
• Nabuhiro N, Souichiro O, Horacio C, Miyamoto M. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 2003;63:8977–83
   PubMed Web of Science ®Google Scholar
• Siddik ZH, Newell DR, Boxall FE, Harrap KR. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 1987;36:1925–32
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP. Liposomal cisplatin: a new cisplatin formulation. Anti-Cancer Drugs 2010;21:732–6
   PubMed Web of Science ®Google Scholar
• Ohta S, Nitta N, Sonoda A, et al. Prolonged local persistence of cisplatin-loaded gelatin microspheres and their chemoembolic anticancer effect in rabbits. Eur J Radiol 2009;72:534–40
   PubMed Web of Science ®Google Scholar
• Fang JY, Hsu SH, Leu YL, Hu JW. Delivery of cisplatin from pluronic co-polymer systems: liposome inclusion and alginate coupling. J Biomater Sci Polym Ed 2009;20:1031–47
   PubMed Web of Science ®Google Scholar
• Tomalia DA. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog Polym Sci 2005;30:294–324
   Web of Science ®Google Scholar
• Tomalia DA, Fréchet JMJ, eds. Dendrimers and other dendritic polymers. Chichester: J Wiley & Sons Ltd; 2001
   Google Scholar
• Huang X, Wu Z, Gao W, et al. Polyamidoamine dendrimers as potential drug carriers for enhanced aqueous solubility and oral bioavailability of silybin. Drug Dev Ind Pharm 2011;37:419–27
   PubMed Web of Science ®Google Scholar
• Chauhan AS, Jain NK, Diwan PV. Pre-clinical and behavioral toxicity profile of PAMAM dendrimer in mice. Proc R Soc A 2010;466:1535–50
   Google Scholar
• Chauhan AS, Diwan PV, Jain NK, Tomalia DA. Simple terminal functionalized poly(amidoamine) (PAMAM) dendrimers: in vivo active macromolecular anti-inflammatory agents. Biomacromolecule 2009;5:1195–202
   Google Scholar
• Chauhan AS, Svenson S, Reyna L, Tomalia DA. Solubility enhancement propensity of PAMAM nanoconstructs. Mater Matters Nanomater 2007;2:24–7
   Google Scholar
• Chauhan AS, Jain NK, Diwan PV. Solubility enhancement of indomethacin using dendrimer complex and bio-disposition profile of these complexes in arthritic rats. J Drug Targeting 2004;12:575–83
   PubMed Web of Science ®Google Scholar
• Chauhan AS, Sridevi S, Chalasani KB, et al. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J Control Release 2003;90:335–43
   PubMed Web of Science ®Google Scholar
• Svenson S, Chauhan AS. Dendrimers for enhanced drug solubilization. Nanomedicine 2008;3:679–702
   PubMed Web of Science ®Google Scholar
• Kulhari H, Deep Pooja, Prajapati SK, Chauhan AS. Performance evaluation of PAMAM dendrimer based Simvastatin formulations. Int J Pharm 2011;405:203–9
   PubMed Web of Science ®Google Scholar
• Asthana A, Chauhan AS, Diwan PV, Jain NK. Poly (amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient. AAPS Pharm Sci Tech 2005;6:E536–42
   PubMed Web of Science ®Google Scholar
• Kulhari H, Kulhari DP, Prajapati SK, Chauhan AS. Pharmacokinetic and pharmacodynamic studies of poly(amido)amine dendrimer based simvastatin oral formulations for the treatment of hypercholesterolemia. Mol Pharm 2013;10:2528–33
   PubMed Web of Science ®Google Scholar
• Kirkpatrick GJ, Plumb JA, Sutcliffe OB, et al. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin. J Inorg Biochem 2011;105:1115–22
   PubMed Web of Science ®Google Scholar
• Yellepeddi VK, Kumar A, Maher DM, et al. Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT. Anticancer Res 2011;31:897–906
   PubMed Web of Science ®Google Scholar
• Haririan I, Alavidjeh SM, Khorrramizadeh MR, et al. Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines. Int J Nanomed 2010;5:63–75
   PubMed Web of Science ®Google Scholar
• Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 1999;10:767–76
   PubMed Web of Science ®Google Scholar
• Yotsuyanagi T, Usami M, Noda Y, Nagata M. Computational consideration of cisplatin hydrolysis and acid dissociation in aqueous media: effect of total drug concentrations. Int J Pharm 2002;246:95–104
   PubMed Web of Science ®Google Scholar